News

Pfizer fails in late-stage trial for sickle cell disease therapy

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...
Crain's New York Business11d

Pfizer lifts profit view as cuts offset flat sales outlook

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer's sickle-cell treatment efforts falter as drug fails study

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

Pfizer Raises Profit Outlook Despite Uncertainty Over Tariffs, Drug Prices

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
mlive on MSN2d

‘Potential exposure’ at Portage Pfizer plant sends people to hospital, MIOSHA investigating

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer raises 2025 profit forecast as cost-cutting program gains traction

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer: This Is What Bulls Waited For

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer's sickle cell drug fails late-stage trial

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...